-
AstraZeneca Korea reapplies for Lynparza reimbursement in prostate cancer
22 Apr 2025 02:24 GMT
… inhibitor Lynparza (olaparib) for the prostate cancer indication.
Korea Biomedical Review has … BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) whose disease has … that the combination of abiraterone (Zytiga) and a PARP inhibitor is …
-
Broader ARPI Arsenal Enables Personalized, Cost-Conscious Treatment Selection in Prostate Cancer
21 Apr 2025 16:07 GMT
… the treatment of prostate cancer: abiraterone acetate (Zytiga), apalutamide ( … metastatic-castration-resistant-prostate-cancer
FDA approves … -castration-sensitive-prostate-cancer
FDA approves … metastatic-hormone-sensitive-prostate-cancer
FDA approves …
-
Erleada Reduces Risk of Death in Metastatic Prostate Cancer Subset
15 Apr 2025 21:37 GMT
… approved Zytiga with prednisone for high-risk metastatic castration-sensitive prostate cancer in … and Zytiga or Xtandi in patients with metastatic castration-sensitive prostate cancer” by …
-
Apalutamide Boosts 24-Month OS in Real-World Population With Metastatic Castration-Sensitive Prostate Cancer
14 Apr 2025 18:04 GMT
… patients treated with abiraterone acetate (Zytiga; HR, 0.74; 95% … -approves-enzalutamide-metastatic-castration-sensitive-prostate-cancer
Armstrong AJ, Szmulewitz RZ, … high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival …
-
Janssen Korea’s Zytiga secures expanded reimbursement for 1st-line prostate cancer treatment
02 Apr 2025 07:19 GMT
… , Janssen Korea's prostate cancer drug Zytiga will be available with prednisolone … , "Zytiga is one of the first-line treatments for prostate cancer in … to expand access to prostate cancer treatment since Zytiga's reimbursement in …
-
First Patent Dosed With Pocenbrodib in Trial for Metastatic Prostate Cancer
22 Mar 2025 01:31 GMT
… castration-resistant prostate cancer, according to … castration-resistant prostate cancer who have … , indicating reduced prostate cancer activity.
Preliminary antitumor … Zytiga, Lynparza or Pluvicto, in adults with metastatic castration-resistant prostate cancer …
-
Global Prostate Cancer Market to Reach USD 29.2 Billion by 2035, Driven by Aging Population and Awareness | Future Market Insights, Inc.
10 Mar 2025 00:30 GMT
… drugs such as Zytiga. A growing … prostate cancer chemotherapy (taxotere and jevtana), prostate cancer immunotherapy (provenge), prostate cancer … targeted therapy (xofigo) and other prostate cancer …
-
Updated Clinical Trial Data Reflect Efforts to Optimize IO Combos in Non-ccRCC and MIBC, Fine-Tune ADT-Based Regimens in Prostate Cancer
25 Feb 2025 23:52 GMT
… in metastatic hormone-sensitive prostate cancer (mHSPC).
In a … driven strategies in prostate cancer.
Barata is the … ARPIs, including abiraterone acetate [Zytiga], enzalutamide [Xtandi], and … metastatic castration-resistant prostate cancer setting. The question …
-
Radioligand Therapies and Emerging Targets Drive Innovation in Prostate Cancer Management
24 Feb 2025 23:47 GMT
… of radioligand therapies in prostate cancer; discussed emerging targets … the future management of prostate cancer?
Barata: The [role … advanced metastatic castration-resistant prostate cancer [(mCRPC) who have … with abiraterone acetate [Zytiga] in the mCRPC …
-
Metastatic Castration-Resistant Prostate Cancer Market to Register Stupendous Growth During the Study Period (2020–2034) Owing to the Active Participation of Pharma Companies | DelveInsight
17 Feb 2025 18:00 GMT
… for prostate cancer treatment. Additionally, AstraZeneca is exploring capivasertib in combination with ZYTIGA … Castration-Resistant Prostate Cancer Therapies
AKEEGA, JEVTANA, LYNPARZA, TALZENNA, XOFIGO, XTANDI, ZYTIGA, PLUVICTO …
About
© 1995-2025